{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:15:50Z","timestamp":1788239750559,"version":"build-2803163510"},"reference-count":40,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Brolucizumab is an intravitreal anti-vascular endothelial growth factor (anti-VEGF) agent developed to improve retinal drying and treatment durability in diabetic eye disease. However, its overall efficacy and safety in diabetic macular edema (DME) and diabetic retinopathy remain uncertain because available trials differ in population, comparator, dosing schedule, and follow-up. Methods: We searched PubMed, Cochrane Library, Scopus, and Web of Science from inception to 25 April 2026. Randomized controlled trials evaluating intravitreal brolucizumab in adults with DME, diabetic retinopathy, or proliferative diabetic retinopathy (PDR) were included. Comparators were aflibercept, panretinal photocoagulation, or other active\/conventional treatments. The main efficacy outcomes were change in best-corrected visual acuity (BCVA) and central subfield thickness\/central subfield foveal thickness (CST\/CSFT). Safety outcomes included ocular, non-ocular, serious ocular, and serious non-ocular adverse events. Random-effects meta-analyses were performed. Results: Five reports representing four phase 3 randomized controlled trials were included, enrolling 2132 participants overall; the four-trial primary 6 mg analyses included 1942 participants. Brolucizumab was not associated with a significant improvement in BCVA compared with control treatment (mean difference [MD], 1.21 letters; 95% confidence interval [CI], \u22121.12 to 3.54; p = 0.3; I2 = 85.1%). However, brolucizumab significantly reduced CST\/CSFT (MD \u221224.45 \u00b5m, 95% CI \u221247.43 to \u22121.47; p = 0.0370; I2 = 78.2%). No statistically significant differences were detected between groups in the assessed safety outcomes, including ocular adverse events (risk ratio [RR], 0.88), non-ocular adverse events (RR 1.00), serious ocular adverse events (RR 0.63), and serious non-ocular adverse events (RR 0.89). Separate analyses of brolucizumab-specific ocular events showed no statistically significant differences for intraocular inflammation (RR 2.35, 95% CI 0.36\u201315.42), retinal vasculitis (RR 2.10, 95% CI 0.22\u201320.10), or retinal vascular occlusion (RR 2.13, 95% CI 0.46\u20139.87); however, estimates were imprecise because of the small number of events. Conclusions: Across the four included trials, brolucizumab was not associated with a statistically significant difference in BCVA compared with control treatment. In the three DME trials, brolucizumab achieved a greater reduction in CST\/CSFT. It may be useful for selected DME patients, while its role in PDR requires longer-term evidence.<\/jats:p>","DOI":"10.3390\/jcm15176518","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:47:19Z","timestamp":1787572039000},"page":"6518","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Efficacy of Brolucizumab in the Treatment of Patients with Diabetic Macular Edema and Diabetic Retinopathy: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"15","author":[{"given":"Sharifa N.","family":"Bourisly","sequence":"first","affiliation":[{"name":"Mubarak Alkabeer Hospital, Ministry of Health, P.O. Box 5, Safat, Kuwait City 13001, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatmah S.","family":"Semairan","sequence":"additional","affiliation":[{"name":"Farwaniya Hospital, Ministry of Health, P.O. Box 5, Safat, Kuwait City 13001, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3796-5337","authenticated-orcid":false,"given":"Yousef Mesaed","family":"Al-Shammari","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Al-Bahar Eye Center, Ibn Sina Hospital, Ministry of Health, P.O. Box 5, Safat, Kuwait City 13001, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Alali","sequence":"additional","affiliation":[{"name":"Mubarak Alkabeer Hospital, Ministry of Health, P.O. Box 5, Safat, Kuwait City 13001, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulwa Abbas","family":"Alfoudari","sequence":"additional","affiliation":[{"name":"Aljahra Hospital, Ministry of Health, P.O. Box 5, Safat, Kuwait City 13001, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz F.","family":"Abdulkareem","sequence":"additional","affiliation":[{"name":"College of Medicine and Medical Sciences, Arabian Gulf University, Salmaniya, Manama P.O. Box 26671, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2337-6588","authenticated-orcid":false,"given":"Abdullah M.","family":"Alharran","sequence":"additional","affiliation":[{"name":"College of Medicine and Medical Sciences, Arabian Gulf University, Salmaniya, Manama P.O. Box 26671, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jamaophthalmol.2026.1008","article-title":"Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial","volume":"144","author":"Wolf","year":"2026","journal-title":"JAMA Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 Diabetes Mellitus in Adults: Pathogenesis, Prevention and Therapy","volume":"9","author":"Lu","year":"2024","journal-title":"Sig. Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s40123-022-00547-2","article-title":"Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology","volume":"11","author":"Kozak","year":"2022","journal-title":"Ophthalmol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40942-024-00603-y","article-title":"Diabetic Macular Edema (DME): Dissecting Pathogenesis, Prognostication, Diagnostic Modalities along with Current and Futuristic Therapeutic Insights","volume":"10","author":"Sakini","year":"2024","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"107307","DOI":"10.1016\/j.ejps.2025.107307","article-title":"Diabetic Retinopathy in Focus: Update on Treatment Advances, Pharmaceutical Approaches, and New Technologies","volume":"214","author":"Ciorba","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"P75","DOI":"10.1016\/j.ophtha.2024.12.020","article-title":"Diabetic Retinopathy Preferred Practice Pattern\u00ae","volume":"132","author":"Lim","year":"2025","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.oret.2024.05.017","article-title":"Long-Term Treatment Patterns for Diabetic Macular Edema","volume":"8","author":"Kuo","year":"2024","journal-title":"Ophthalmol. Retin."},{"key":"ref_9","first-page":"e22471","article-title":"Review of Studies Comparing Panretinal Photocoagulation and Anti-Vascular Endothelial Growth Factor Therapy in the Treatment of Proliferative Diabetic Retinopathy","volume":"14","author":"Gunasekaran","year":"2022","journal-title":"Cureus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"E001","DOI":"10.1017\/S0952523820000115","article-title":"The Neuroscience of Diabetic Retinopathy","volume":"38","author":"Antonetti","year":"2021","journal-title":"Vis. Neurosci."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Alali, N.M., Aljahdali, A., AlBalawi, H.B., Al Jarallah, O.J., Al Zaid, S.M., Abuallut, I., ALMarek, F., Shajry, I., Alotaibi, Y.A., and Hazzazi, M.A. (2025). Effectiveness, Safety, and Real-World Experience of Brolucizumab: A Systematic Review. Pharmaceuticals, 18.","DOI":"10.3390\/ph18111620"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-Week Results from Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","article-title":"KESTREL and KITE Phase 3 Studies: 100-Week Results with Brolucizumab in Patients with Diabetic Macular Edema","volume":"260","author":"Wykoff","year":"2024","journal-title":"Am. J. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamaophthalmol.2023.5248","article-title":"Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial","volume":"141","author":"Singh","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_16","first-page":"ED000142","article-title":"Updated Guidance for Trusted Systematic Reviews: A New Edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"2019","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_17","unstructured":"(2026, February 14). EndNote\u2014The Best Citation & Reference Management Tool. Available online: https:\/\/endnote.com\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A Web and Mobile App for Systematic Reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_19","unstructured":"Rohatgi, A. (WebPlotDigitizer, 2024). WebPlotDigitizer, Version 5.2."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An Emerging Consensus on Rating Quality of Evidence and Strength of Recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"ref_22","unstructured":"Harrer, M., Cuijpers, P., Furukawa, T., and Ebert, D.D. (2026, March 13). Companion R Package for the Guide Doing Meta-Analysis in R. Available online: https:\/\/dmetar.protectlab.org\/."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10916","DOI":"10.1002\/ece3.6747","article-title":"A Contrast of Meta and Metafor Packages for Meta\u2010analyses in R","volume":"10","author":"Lortie","year":"2020","journal-title":"Ecol. Evol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e70063","DOI":"10.1111\/jebm.70063","article-title":"Examining and Interpreting Doi Plot Asymmetry in Meta\u2010Analyses of Randomized Controlled Trials","volume":"18","author":"Rousou","year":"2025","journal-title":"J. Evid. Based Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.oret.2025.10.013","article-title":"Brolucizumab for Diabetic Macular Edema in Participants with\/without Prior Anti-VEGF Exposure","volume":"10","author":"Ip","year":"2026","journal-title":"Ophthalmol. Retin."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wallsh, J.O., and Gallemore, R.P. (2021). Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options. Cells, 10.","DOI":"10.3390\/cells10051049"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"15903","DOI":"10.1038\/s41598-026-47416-7","article-title":"Efficacy of Anti-VEGF Therapy for Different OCT Patterns in Diabetic Macular Edema and the Correlation between Ellipsoid Zone Integrity and Visual Acuity","volume":"16","author":"Shi","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41433-019-0522-z","article-title":"Relationship between Duration and Extent of Oedema and Visual Acuity Outcome with Ranibizumab in Diabetic Macular Oedema: A Post Hoc Analysis of Protocol I Data","volume":"34","author":"Sadda","year":"2020","journal-title":"Eye"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jamaophthalmol.2015.4599","article-title":"Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema","volume":"134","author":"Wells","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"E008","DOI":"10.1017\/S0952523820000097","article-title":"Diabetic Photoreceptors: Mechanisms Underlying Changes in Structure and Function","volume":"37","author":"Becker","year":"2020","journal-title":"Vis. Neurosci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/14712598.2021.1915278","article-title":"Brolucizumab: A Novel Anti-VEGF Humanized Single-Chain Antibody Fragment for Treating w-AMD","volume":"21","author":"Traverso","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Callan, A., Heckman, J., Tah, G., Lopez, S., Valdez, L., and Tsin, A. (2025). VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26114992"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40123-025-01108-z","article-title":"The Impact of Disease Activity Criteria on Extending Injection Intervals in Real-World Patients with Neovascular Age-Related Macular Degeneration","volume":"14","author":"Bhatia","year":"2025","journal-title":"Ophthalmol. Ther."},{"key":"ref_34","first-page":"e52676","article-title":"Diabetic Macular Edema Management: A Review of Anti-Vascular Endothelial Growth Factor (VEGF) Therapies","volume":"16","author":"Cheema","year":"2024","journal-title":"Cureus"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s13300-023-01410-8","article-title":"Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis","volume":"14","author":"Sydnor","year":"2023","journal-title":"Diabetes Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.2147\/OPTH.S487055","article-title":"Brolucizumab versus Aflibercept in Patients with Diabetic Macular Edema: A Meta-Analysis of Randomized Controlled Trials","volume":"18","author":"Justino","year":"2024","journal-title":"Clin. Ophthalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion\u2013Related Events with Brolucizumab","volume":"128","author":"Srivastava","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_38","unstructured":"National Institute for Health and Care Excellence (NICE) (2026, May 10). Brolucizumab for Treating Diabetic Macular Oedema. Technology Appraisal Guidance TA820. Available online: https:\/\/www.nice.org.uk\/guidance\/ta820."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","article-title":"Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results from the IRIS Registry and Komodo Healthcare Map","volume":"140","author":"Khanani","year":"2022","journal-title":"JAMA Ophthalmol."},{"key":"ref_40","unstructured":"(2026, May 10). Recommendations|Diabetic Retinopathy: Management and Monitoring|Guidance|NICE. Available online: https:\/\/www.nice.org.uk\/guidance\/ng242\/chapter\/Recommendations."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6518\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:23:56Z","timestamp":1788236636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,23]]},"references-count":40,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176518"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176518","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,23]]}}}